Gain Therapeutics, Inc.Gain Therapeutics, Inc.Gain Therapeutics, Inc.

Gain Therapeutics, Inc.

No trades
See on Supercharts

Price target

7.400.000.00%
The 5 analysts offering 1 year price forecasts for GANX have a max estimate of — and a min estimate of —.

Analyst rating

Based on 5 analysts giving stock ratings to GANX in the past 3 months.

EPS

‪0.00‬
Reported
Estimate
Reported
Estimate
Surprise

Revenue

‪0.00‬
Reported
Estimate
Reported
Estimate
Surprise
Be warned

Frequently Asked Questions


GANX EPS for the last quarter is −0.17 USD despite the estimation of −0.21 USD. In the next quarter EPS is expected to reach −0.19 USD. Track more of Gain Therapeutics, Inc. financials and stay on top of what is up with the company.
In the next quarter Gain Therapeutics, Inc. revenue is expected to reach ‪23.33 K‬ USD. Check out Gain Therapeutics, Inc. revenue and earnings and make informed decisions.
According to analysts, GANX price target is 7.40 USD with a max estimate of 10.00 USD and a min estimate of 5.00 USD. Check if this forecast comes true in a year, meanwhile watch Gain Therapeutics, Inc. stock price chart and keep track of the current situation with GANX news and stock market news.
We've gathered opinions of 5 analysts rating GANX stock in the past 3 months. Most of them backed up the strong buy trend, and after taking into account other opinions, the overall rating was calculated as strong buy. Note that it's not a trading advice — your own analysis is still required.